Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy.

GUIDELINE TITLE
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy.

BIBLIOGRAPHIC SOURCE(S)
National Institute for Health and Clinical Excellence (NICE). Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Jun. 32 p. (Technology appraisal guidance; no. 171).

GUIDELINE STATUS
This is the current release of the guideline.

RECOMMENDATIONS
MAJOR RECOMMENDATIONS
Lenalidomide in combination with dexamethasone is recommended, within its licensed indication, as an option for the treatment of multiple myeloma only in people who have received two or more prior therapies, with the following condition:

The drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the manufacturer.
People currently receiving lenalidomide for the treatment of multiple myeloma, but who have not received two or more prior therapies, should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

open here to see the full-text:
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy.